Loading clinical trials...
Loading clinical trials...
An Expanded Access Study for Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Therapy in Japan
Conditions
Interventions
Venetoclax
Cytarabine
Locations
16
Japan
NHO Nagoya Medical Center /ID# 223671
Nagoya, Aichi-ken, Japan
Aichi Cancer Center Hospital /ID# 223134
Nagoya, Aichi-ken, Japan
University of Fukui Hospital /ID# 223133
Yoshida-gun, Fukui, Japan
Kyushu University Hospital /ID# 223136
Fukuoka, Fukuoka, Japan
Gunmaken Saiseikai Maebashi Hospital /ID# 223301
Maebashi, Gunma, Japan
National Hospital Organization Mito Medical Center /ID# 223392
Higashi Ibaraki-gun, Ibaraki, Japan
Start Date
October 5, 2020
Primary Completion Date
April 15, 2021
Completion Date
April 15, 2021
Last Updated
May 5, 2022
NCT07500441
NCT05756777
NCT05768932
NCT07451912
NCT06660368
NCT05143996
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions